Similarly, PLX3397 alone was not found effective in treating recurrent GBMs in a phase II clinical trial, suggesting that a combined therapy may be needed to augment the potential efficacy of targeting CSF-1R in GBM [13]. The gene discussed is CSF1R; the disease is glioblastoma.